Hosted on MSN23d
EMA approves Takeda’s Takhzyro pre-filled pen option for HAEThe European Medicines Agency (EMA) has approved an additional 2 mL pre-filled pen option for subcutaneous administration of Takeda’s Takhzyro (lanadelumab), aimed at treating hereditary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback